Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma
J Budka, D Debowski, S Mai, M Narajczyk, S Hac… - Pharmaceutics, 2024 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) presents a formidable challenge with high
lethality and limited effective drug treatments. Its heightened metastatic potential further …
lethality and limited effective drug treatments. Its heightened metastatic potential further …